PD-1/PD-L1 inhibitors and radiotherapy have potential synergistic anti-tumor immunomodulatory effects, with radiotherapy providing a more suitable immune microenvironment for subsequent PD-1/PD-L1 inhibitor therapy, while PD-1/PD-L1 inhibitors can attenuate radioresistance and enhance distant effects (Chen et al., 2020). The gene discussed is PDCD1; the disease is neoplasm.